MCL-1及其抑制剂在乳腺癌中的应用  

Application of MCL-1 and its inhibitors in breast cancer

作　　者：狄潘潘 DI Pan-pan(Pharmacy Intravenous Admixture Services,the People's Hospital of Bozhou,Bozhou ANHUI 236800,China)

机构地区：[1]亳州市人民医院静配中心,安徽亳亳州236800

出　　处：《中国新药与临床杂志》2023年第5期279-283,共5页Chinese Journal of New Drugs and Clinical Remedies

摘　　要：髓样细胞白血病(MCL)-1蛋白是一种抗凋亡蛋白,已被证实在多种癌症如多发性骨髓瘤、肺癌、急性髓系白血病及乳腺癌中发挥重要作用。有研究表明,MCL-1在多种类型乳腺癌中高表达,是导致乳腺癌患者预后不良及对化疗药产生耐药的重要因素之一。同时,MCL-1也是三阴性乳腺癌的重要生存蛋白,因此MCL-1可作为抗乳腺癌药物的作用靶点。目前多个研究证实MCL-1抑制剂如S63845、EU-5346、JY-1-106及VU661013对多种类型的乳腺癌细胞有良好的抑制作用。Myeloid cell leukemin(MCL)-1 protein is an anti-apoptotic protein that has been proven to play an important role in a variety of cancers,such as multiple myeloma,lung cancer,acute myeloid leukemia and breast cancer.Some studies have shown that MCL-1 is highly expressed in many types of breast cancer,and it is one of the important factors leading to poor prognosis of breast cancer patients and resistance to chemotherapy drugs.At the same time,MCL-1 is also an important survival protein for triple-negative breast cancer.Therefore,MCL-1 can be used as the target of antibreast cancer drugs.At present,many studies have confirmed that MCL-1 inhibitors such as S63845,EU-5346,JY-1-106 and VU661013 have good inhibitory effects on various types of breast cancer cells.

关 键 词：乳腺肿瘤 凋亡调节蛋白质类 分子靶向治疗 髓样细胞白血病-1 

分 类 号：R737.9[医药卫生—肿瘤] R979.1[医药卫生—临床医学]